Daily Market Research Report

January 09, 2026

Alpha Signal Monitor

Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.

Today's Coverage: - Gold ETF Outlook: Institutional perspectives on gold-backed ETFs - Stock Ratings: Latest analyst ratings and target prices for our watchlist - IPO Calendar: Upcoming initial public offerings and market debuts

Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA, AVGO, TSM

This report is generated using advanced AI research capabilities with real-time market data access.

Gold ETFs — Institutional Outlook as of January 9, 2026

Trading Idea: Buy Rationale (TL;DR): Most major houses (GS, JPM, BofA, MS, HSBC, DB) project new or near‑record gold prices into 2026 on the back of robust official‑sector demand, resuming ETF inflows, and easier policy/softer real yields; only Citi is notably cautious. This supports long exposure to physically backed gold ETFs (GLD, IAU, BAR). (straitstimes.com)

2025 saw a 64% gold surge amid tariffs/geopolitics; into 2026 banks expect continued support from central‑bank buying and renewed ETF inflows as global rate cuts weigh on real yields and the dollar. WGC data show five straight months of ETF inflows into Oct‑2025 and the strongest half‑year inflow since H1‑2020; banks emphasize official purchases as a structural tailwind. Near‑term, commodity‑index rebalancing is a source of volatility. (reuters.com)

Key Drivers - Persistent central‑bank purchases (EM reserve diversification). - Renewed net inflows to gold ETFs after multi‑year outflows. - Fed and global rate‑cut cycles pressuring real yields and the USD. - Policy/geopolitical uncertainty (tariffs, fiscal risks, Fed independence debates) elevating safe‑haven demand. - Tight physical market conditions and strong Asia demand/premiums.

Risk Considerations - Upside surprises to growth/inflation that push real yields higher or stall Fed cuts. - Stronger USD reducing non‑USD gold returns. - A sharp slowdown/reversal in central‑bank buying or ETF flows. - Positioning washouts around index rebalancing or profit‑taking. - Demand destruction in jewelry/retail from high prices, especially in India/EM.

Consensus skew is higher for 2026, with $4.5k–$5.0k/oz endpoints common among bullish houses and one notable neutral (Citi). For GLD/IAU/BAR, we favor maintaining core long exposure and buying dips caused by mechanical flows (e.g., index rebalancing), while sizing for elevated two‑way volatility. Watch real yields/USTs, USD trend, and official‑sector/ETF flow data as key triggers. (ft.com)

Stock Ratings

Error retrieving stock ratings information: Connection error.

IPO Calendar

Timeframe: January 9, 2026 to February 9, 2026 (U.S. equity markets)

As of January 9, 2026, the U.S. IPO calendar is light following the typical early‑January lull; only one operating‑company IPO is firmly scheduled (Aktis Oncology), and exchange calendars show no additional deals set for next week at this time. Calendars often finalize just 7–10 days ahead of pricing, so later‑January slots can still fill quickly. (globenewswire.com) Notable themes: (1) Biotech leads the tape to start 2026, with Aktis’ upsized deal supported by a $100 million anchor from Eli Lilly, suggesting investor interest in radiopharmaceutical platforms. (reuters.com) (2) SPAC activity has reopened around the turn of the year (e.g., Bleichroeder Acquisition Corp. II units listed Jan 8), though SPAC calendars also tend to firm up only days in advance. (globenewswire.com) Overall, issuers continue to watch volatility and will likely cluster pricings into short windows as market conditions allow. (stockanalysis.com)

Aktis Oncology, Inc. (AKTS)

• Expected listing date: January 9, 2026
• Price range: Priced at $18.00 per share (range was $16.00–$18.00)
• Shares offered: 17,650,000 primary shares offered; 30‑day option for 2,647,500 additional shares (overallotment)
• Exchange: Nasdaq Global Select Market
• Lead underwriters: J.P. Morgan, BofA Securities, Leerink Partners, TD Cowen
• Business summary: Clinical‑stage biotech developing alpha‑emitting radiopharmaceuticals (miniprotein radioconjugates) targeting prevalent solid tumors. Lead candidate Ac‑AKY‑1189 (targets Nectin‑4) is in a Phase 1b trial; a second program targeting B7‑H3 is planned to enter the clinic in 2026. (renaissancecapital.com)
• Notes: IPO upsized ahead of pricing; Eli Lilly indicated an interest in ~$100 million of shares. Registration (S‑1, File No. 333‑292283) was declared effective Jan 8, 2026. Expected to begin trading Jan 9, 2026; closing expected Jan 12, 2026, subject to customary conditions. (reuters.com)
• Sources: Aktis Oncology Announces Pricing of its Upsized Initial Public Offering (GlobeNewswire, Jan 8, 2026), Reuters: Aktis Oncology prices upsized US IPO at $18 per share (Jan 9, 2026), Renaissance Capital: Aktis Oncology prices IPO at $18 (Jan 8, 2026), SEC: Aktis Oncology S‑1 (File No. 333‑292283) – effectiveness noted Jan 8, 2026

Payward, Inc. (d/b/a Kraken)

• Lead underwriters: Morgan Stanley, Goldman Sachs
• Business summary: U.S.-based cryptocurrency exchange offering spot and derivatives trading, staking, and related services to retail and institutional clients; confidentially filed for a U.S. IPO in November 2025 and is preparing for a potential listing as early as 1Q26, subject to SEC review and market conditions. (bloomberg.com)
• Notes: Timing in the next 30 days is uncertain; details such as share count, price range, exchange, and final bookrunners have not been formally announced. Reports indicate the company is working with Morgan Stanley and Goldman Sachs; plans could change. (news.bloomberglaw.com)
• Sources: Bloomberg: Crypto Exchange Kraken Files Confidentially for US IPO (Nov 19, 2025), Reuters: Crypto exchange Kraken confidentially files for US IPO (Nov 19, 2025), Bloomberg Law: Kraken has filed confidentially for a US IPO; working with Morgan Stanley and Goldman Sachs (Nov 2025)

IPO dates and terms change frequently and are often confirmed within 7–10 days of pricing; absence from this calendar does not mean an issuer will not price within the timeframe. Information above reflects the status as of Friday, January 9, 2026, and will be updated as new filings, effectiveness notices, and launch announcements appear. (stockanalysis.com)

Sources

• IPO Calendar: https://news.bloomberglaw.com/business-and-practice/crypto-exchange-kraken-files-confidentially-for-us-ipo-listing?utm_source=openai, https://stockanalysis.com/ipos/calendar/?utm_source=openai, https://www.bloomberg.com/news/articles/2025-11-19/crypto-exchange-kraken-files-confidentially-for-us-ipo-listing?utm_source=openai, https://www.globenewswire.com/news-release/2026/01/08/3214998/0/en/Bleichroeder-Acquisition-Corp-II-Announces-the-Pricing-of-250-000-000-Initial-Public-Offering.html?utm_source=openai, https://www.globenewswire.com/news-release/2026/01/09/3215872/0/en/Aktis-Oncology-Announces-Pricing-of-its-Upsized-Initial-Public-Offering.html?utm_source=openai, https://www.renaissancecapital.com/IPO-Center/News/116024/Phase-1-solid-tumor-biotech-Aktis-Oncology-prices-IPO-at-%2418-the-high-end-o?utm_source=openai, https://www.reuters.com/business/healthcare-pharmaceuticals/aktis-oncology-aims-raise-up-3177-million-upsized-us-ipo-2026-01-07/?utm_source=openai

Disclaimer

This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.

Generated on: 2026-01-09 at 11:23 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.

Powered by Alpha Signal Monitor | Market Intelligence Through AI